

Highlights of Analytical Sciences in Switzerland

Division of Analytical Sciences

A Close Look at the Fate of Compounds we are Exposed to

Bertrand Rochat*, Julia Bilat, and Baptiste Grund

*Correspondence: Dr. B. Bochat, Quantitative Mass Spectrometry Facility, University of Lausanne. Centre Hospitalier Universitaire Vaudois. Rte du Bugnon 46. CH-1011 Lausanne, Tel.: +41 21 314 41 58, E-mail: bertrand.rochat@chuv.ch


Keywords: Biotransformation enzymes · Blood · Drug metabolism · Exposome · High-resolution mass spectrometry · Tamoxifen

The exposome was defined by C. P. Wild as non-genetic and encompasses "every exposure to which an individual is subjected from conception to death". An exposome can be endogenous microbes, physical activity, infectious agents, stress, xenobiotics such as pollutants or drugs and so forth and is a new term rather than a new concept. The capacity of new liquid-chromatography mass-spectrometry (LC-MS) to detect, in the same analysis, a large number of molecules (100s to 1000s) at low levels has advanced our understanding of the exposome. These new detectors are LC-high-resolution mass-spectrometers (HR-MS) and are mainly composed of Orbitrap- and Time-Of-Flight-MS.

HR-MS allows for the discrimination between very close ionized molecular masses (m/z for mass-over-charge ratio). For instance, $C_{15}H_{14}O_{3}N$ or $C_{16}H_{16}OS$, ionized by an H^+ adduct, would easily be discriminated by their m/z values: 257.10464 and 257.09946 Da (delta = 5 mDa), respectively. LC-HRMS analysis with full scan acquisition shows an excellent selectivity whereas

1000s of ions are recorded in a LC-MS analysis. HR-MS has shown similar quantitative capabilities in comparison to traditional quantification technology, triple-quadrupole-MS.


We studied the fate of a drug, tamoxifen, taken for three months or more with hv women breast cancer. We discovered over 44 tamoxifen metabolites in their blood that are the result different of biotransformation enzymes, with up to



Typical LC-high-resolution mass-spectrometry analysis. 1) A high resolution (HR) full scan is acquired from sample extracts. 2) The ionized molecules of interest are selected based on their accurate m/z ratio. 3) The extracted ion seven biotransforma- chromatograms are constructed.

tion steps. This underscores that, when we are exposed to one molecule chronically, the body can eventually be exposed to a lot of different derived molecules. We revealed the inter-individual differences in the levels of some tamoxifen metabolites, demonstrating that the effect of a xenobiotic and its metabolites can strongly vary from person to person.

Today, using highresolution mass-spectrometry, the fate of drugs and pollutants in humans can be studied more inare chronically exposed of the exposome.



Michael Waraksa's illustration shows depth and with ease. From how our environment shapes our a single compound we health and underscores the concept

Received: August 28, 2014


to, there are tens of metabolites produced that could have adverse reactions. Although our body is armed to cope with most exposures, a more in-depth analysis allows to relate toxic events, e.g. in a sub-population, and xenobiotic and its various metabolites.

References

C. P. Wild, Int. J. Epidemiol. 2012, 41, 24.

B. Rochat, E. Kottelat, J. McMullen, Bioanalysis 2012, 4, 2939.

E. Dahmane, J. Boccard, C. Csajka, S. Rudaz, L. Décosterd, E. Genin, B. Duretz, M. Bromirski, K. Zaman, B. Testa, B. Rochat, Anal. Bioanal. Chem. 2014, 406, 2627.



Determination coefficient (R²) between relative levels of tamoxifen metabolites and tamoxifen) in 20 patients treated with tamoxifen (TAM). TAM-OHsulf .: Tamoxifen-hydroxy-sulfate. Data reveal high inter-individual variability of tamoxifen metabolite levels with potential outliers (dashed circle).

Can you show us your analytical highlight?

Please contact: Dr. Veronika R. Meyer, EMPA St.Gallen, Lerchenfeldstrasse 5, 9014 St.Gallen Phone: +41 58 765 77 87, Fax: +41 58 765 77 62, Mail to: veronika.meyer@empa.ch